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Abstract
Background: Burkholderia mallei is a zoonotic Gram negative bacterium which primarily infects
solipeds but can cause lethal disease in humans if left untreated. The effect of two antibiotics with
different modes of action on Burkholderia mallei strain ATCC23344 was investigated by using in vitro
and in vivo studies.
Results: Determination of minimal inhibitory concentrations (MICs) in vitro was done by the agar
diffusion method and the dilution method. The MICs of levofloxacin and ceftazidime were in the
similar range, 2.5 and 5.0 μg/ml, respectively. Intracellular susceptibility of the bacterium to these
two antibiotics in J774A.1 mouse macrophages in vitro was also investigated. Macrophages treated
with antibiotics demonstrated uptake of the drugs and reduced bacterial loads in vitro. The efficacy
of ceftazidime and levofloxacin were studied in BALB/c mice as post-exposure treatment following
intranasal B. mallei infection. Intranasal infection with 5 × 105 CFUs of B. mallei resulted in 90% death
in non-treated control mice. Antibiotic treatments 10 days post-infection proved to be effective in
vivo with all antibiotic treated mice surviving to day 34 post-infection. The antibiotics did not result
in complete clearance of the bacterial infection and presence of the bacteria was found in lungs and
spleens of the survivors, although bacterial burden recovered from levofloxacin treated animals
appeared reduced compared to ceftazidime.
Conclusion: Both antibiotics demonstrated utility for the treatment of glanders, including the
ability for intracellular penetration and clearance of organisms in vitro.
Background
Burkholderia mallei, the causative agent of glanders, a pri-
mary equine disease, is a Gram-negative, facultative intra-
cellular bacterium which can be transmitted to humans
with fatal consequences [1]. Human infections typically
occur in people who have direct contact with glanderous
animals such as veterinarians, farmers or laboratory work-
ers. The most likely route of transmission involves contact
of infectious exudates with cuts and abrasions or with
mucosal membranes. B. mallei are also highly infectious
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organisms by aerosol and it is widely believed that it har-
bors the potential for use as a biological weapon [2]. In
fact, the bacterium was one of the first agents used in bio-
logic warfare during the American Civil War, World Wars
I and II, and Russian invasion of Afghanistan. Conse-
quently, it has been placed on the CDC category B agent
list [3]. Inhalation of aerosol or dust containing B. mallei
can lead to septicemia, pulmonary or chronic infections
of the muscle, liver and spleen. The disease has a 95% case
fatality rate for untreated septicemia infections and a 50%
case fatality rate in antibiotic-treated individuals [4]. The
ability of B. mallei to cause severe, rapidly fatal invasive
infection initiated via aerosol in animals and humans,
coupled with intrinsic resistance to antibiotics and diag-
nostic difficulty at early stage of disease make the bacte-
rium a good candidate as a possible biological threat
agent [5,6]. Our knowledge of pathogenesis of disease due
to B. mallei is minimal. The disease was eliminated from
domestic animals in the United States during the 1940s
and the last reported naturally acquired human case in the
United States occurred in 1945. There is little data availa-
ble on antibiotic treatment of glanders and human cases
are treated with the same regimens used for melioidosis,
an endemic disease in Southeast of Asia and Northern
Australia, caused by Burkholderia pseudomallei. Only one
case of laboratory-acquired human glanders was reported
to CDC recently [7]. This single human case of glanders
corroborated in vitro data with in vivo efficacy for the B.
mallei ATCC 23344 strain when a combination of intrave-
nous doxycycline plus imipenem followed by oral doxy-
cycline plus azithromycin successfully controlled a
disseminated infection [7]. However, at present, the treat-
ment of B. mallei with antibiotic therapy is still not well
established and no effective vaccines are available.
Few in vitro antibiotic susceptibility studies for B. mallei
have been performed. The antibiotic susceptibility of B.
mallei is similar to that of B. pseudomallei, with resistance
to a number of antibiotics [8]. Both organisms appear to
be sensitive to imipenem and doxycycline, while most
strains are susceptible to ceftazidime, ciprofloxacin, and
piperacilin [9]. Unfortunately clinical experience with B.
pseudomallei  infections has shown that despite good in
vitro  activity, an antibiotic may be ineffective in vivo
[10,11]. We chose ceftazidime, highly recommended drug
for treatment of melioidosis. Ceftazidime belongs to the
beta-lactam group, a broad spectrum antibiotic, structur-
ally and pharmacologically related to penicillins, which
work by inhibiting the bacterial cell wall synthesis. This
third generation cephalosporin is effective against Pseu-
domonas  and other Gram-negative bacteria. The second
antibiotic chosen, levofloxacin, belongs to the quinolone
group which inhibits the bacterial DNA gyrase in Gram-
negative bacteria, thereby inhibiting DNA replication and
transcription. Quinolones can enter cells easily and there-
fore are often used to treat intracellular pathogens. As
there is a need for effective treatment and post-exposure
prophylaxis, the objective of this study was to assess the in
vitro  susceptibilities of these antibiotics with different
modes of action and compare with efficacy in macro-
phages and mice infected with B. mallei.
Results
Susceptibility testing, MIC determination
MICs were determined by the agar diffusion method and
dilution method. The results from the agar diffusion
method are listed in Tables 1 and 2. Our results indicate
that B. mallei strain ATCC 23344 is susceptible to a con-
centration as low as 10 μg/ml of ceftazidime and 25 μg/ml
of levofloxacin comparable to our E. coli control strain.
The MICs were further evaluated by the dilution method
for confirmation, resulting in 5 μg/ml of ceftazidime or
2.5 μg/ml of levofloxacin sufficient to inhibit the growth
of B. mallei in LBG after 18–24 h incubation at 37°C
under shaking conditions.
In vivo post-exposure prophylaxis with levofloxacin and 
ceftazidime
The confirmed challenge dose of B. mallei was 4.7 × 105
CFU per animal delivered i.n. in 50 μl PBS (25 μl per
nare). Non-treated control animals became sick within 48
h post-challenge indicated by non-specific signs such as
piloerection and hypo-activity with trembling. The infec-
tion progressed with first deaths observed by day 4 post-
challenge (Fig. 1). By day 6, 80% of non-treated control
animals were dead with only one survivor in this group by
Table 1: Inhibition zone size standards for B. mallei for ceftazidime disks
Disk potency (mg/ml) Zone diameter (mm) for B. mallei ATCC23344 Pattern of resistance/suceptibility
10 > 32 Susceptible
1 > 32 Susceptible
1 × 10-1 32 Susceptible
1 × 10-2 30 Susceptible
1 × 10-3 19 Intermediate
1 × 10-4 < 1 Resistant
1 × 10-5 < 1 Resistant
1 × 10-6 < 1 ResistantBMC Microbiology 2009, 9:88 http://www.biomedcentral.com/1471-2180/9/88
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day 34 (which lacked severe signs consistent with dis-
ease). Ceftazidime and levofloxacin, administrated i.p. 24
hours post-challenge, once a day, for 10 days, significantly
reduced signs of the disease and proved to be effective
with 100% survival rates at day 34 (P < 0.0001) on both
treatments. Histological examination of organs from anti-
biotic treated survivors showed highly enlarged spleens
with large, multifocal abscesses with extension into
abdominal muscles in all infected animals (data not
shown). The spleens of both antibiotic treated and non-
treated animals exhibited a 6–10 fold increase in weight
compared to uninfected healthy animals. Both spleens
and livers showed myeloid hyperplasia. Interestingly, no
lesions were found in the lungs of animals (data not
shown).
Bacterial load at day 34 post-infection
Harvested lungs and spleens from each group of animals
challenged with 5 × 105 CFU/50 μl by i.n. route were sub-
jected to plating on LBG for CFU determination per gram
of organ weight. One animal from levofloxacin treatment
was free of bacteria in spleen and liver. The spleen from
this animal looked normal, was not enlarged, suggesting
that in this particular case, infection was not effective. Bac-
terial counts in the spleens from remaining antibiotic
treated animals were similar, 1.9 × 104 ± 3.9 × 103 CFU/g
for ceftazidime and 1.2 × 104 ± 6.6 × 103 CFU/g for levo-
floxacin and significantly lower from non-treated control
animals (1.8 × 107 ± 8.6 × 106 CFU/g of spleen, Fig. 2). By
day 34 post-infection, bacteria was largely cleared from
the lungs with no significant differences between antibi-
Table 2: Inhibition zone size standards for B. mallei for levofloxacin disks
Disk potency (mg/ml) Zone diameter (mm) for B. mallei ATCC23344 Pattern of resistance/susceptibility
2.5 > 40 Susceptible
2.5 × 10-1 > 40 Susceptible
2.5 × 10-2 27 Susceptible
2.5 × 10-3 10 Intermediatee
2.5 × 10-4 < 1 Resistant
2.5 × 10-5 < 1 Resistant
2.5 × 10-6 < 1 Resistant
2.5 × 10-7 < 1 Resistant
Percentage of survival of BALB/c mice challenged with 5 ×  105 CFUs of B. mallei intranasally (n = 10) Figure 1
Percentage of survival of BALB/c mice challenged 
with 5 × 105 CFUs of B. mallei intranasally (n = 10). 
Treatment with antibiotic started 24 hours post-infection, 
once a day, for 10 days. Ceftazidime (X) and levofloxacin (m) 
were administrated i.p. in doses 100 mg/kg/day and 20 mg/kg/
day respectively. The infection of B. mallei resulted in 90% 
death in non-treated animals (&#x25B3;). All antibiotic 
treated mice survived to day 34 post-infection. Experiment 
performed twice, P < 0.0001 for non-treated vs. antibiotic 
treated animals.
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Reduced B. mallei bacterial burden in antibiotic treated BALB/ c mice Figure 2
Reduced B. mallei bacterial burden in antibiotic 
treated BALB/c mice. Thirty-four days post-challenge, 
surviving levofloxacin treated mice (black bars), ceftazidime 
treated mice (white bars) and untreated control mice 
(crossed bars) were euthanized, and lungs and spleens were 
harvested, weighed and serial dilutions plated for CFU/g tis-
sue weight., * P < 0.05, ** P < 0.01. Errors bars represent 
mean ± SEM.
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otic treated and non-treated animals, although bacterial
burden of the spleens suggested that all animals devel-
oped chronic infection with B. mallei.
The efficacy of ceftazidime and levofloxacin to kill 
intracellular bacteria in vitro
For the determination of intracellular killing of B. mallei
by antibiotics of interest, we performed a bacterial uptake
assay by murine macrophages J774A.1 and evaluated bac-
terial killing for 8 hours of continuous exposure to antibi-
otics in concentrations equal to 100 × MIC for each
compound tested. Murine J774A.1 cells were infected at
an MOI of 25:1 and incubated for 2 hours in the absence
of any antibiotics to allow for uptake (Time 0). At two
hour intervals post-antibiotic exposure, intracellular CFU
were determined resulting in a significant reduction of
intracellular bacteria which continued throughout the
assay (Fig. 3). Media in control wells contained 250 μg/ml
kanamycin for first 2 h postinfection and 100 μg/ml kan-
amycin for the rest of the assay to prevent the growth of
extracellular bacteria[12,13]. Media was free of bacteria
throughout the entire experiment, suggesting efficient
killing of extracellular bacteria (data not shown). At the
end of experiment, after 8 hours post-exposure to antibi-
otics, intracellular B. mallei CFUs were negligible from cell
lysates. Similar results were obtained with lower antibiot-
ics concentration 10 × MIC and lower MOI, 12:1 (data not
shown). The lactate dehydrogenase (LDH) cytotoxicity
assay was performed during bacterial invasion assays to
monitor cytotoxic effects of bacteria on J774A.1 macro-
phages. Throughout the assay LDH levels were below
20%. Cytotoxicity was observed at 8 h in ceftazidime
treated macrophages, reaching 25.7% which may have
contributed to the decrease in recoverable intracellular
bacteria in this treatment. Possible cytotoxic effects of
antibiotics alone was tested in separate experiments for up
to 24 h, including concentrations higher than that tested,
showing no significant LDH levels (data not shown).
Discussion
Limited data of in vitro antibiotic susceptibilities to strains
of B. mallei has been published. The recommendations for
treatments of glanders are largely based on knowledge of
pathogenesis of melioidosis, a human disease caused by a
closely related species B. pseudomallei. Currently, ceftazi-
dime is the first antibiotic of choice for treatment of acute
melioidosis [14]. The previously established MICs of 16
different antimicrobials evaluated against both species
showed most strains susceptible to ceftazidime, cipro-
floxacin, imipenem, and doxycycline [8]. Although B.
mallei has a susceptibility profile similar to B. pseudomallei,
the MICs are usually lower in case of B. mallei [15]. Due to
emergence of resistant strains and cases of disparity
between in vitro susceptibility and clinical outcome of the
treatments for melioidosis, the development of effective
treatments has been difficult [10,16,17]. Both species, B.
mallei and B. pseudomallei, share morphological, biochem-
ical and antigenic characteristics, and could be expected
that similar problems will occur in the case of B. mallei.
There is a need for an extensive evaluation of susceptibil-
ity of antibiotics to these pathogens beyond in vitro stud-
ies.
Animal models to study equine glanders have been estab-
lished [18] while there is a general lack of infection mod-
els that mimic human infection. Among rodents, guinea
pigs and hamsters are most susceptible to glanders [19].
Mice, on the other hand, have similar resistance to glan-
ders infections as humans, which makes this model more
suitable to study therapies for B. mallei. Only intraperito-
neal pathogenesis of glanders has been well described in
the mouse model [20] with more recent studies of the bac-
terium administered via the aerosol or intranasal routes
[21].
Here, we evaluated the susceptibilities in vitro of B. mallei
to ceftazidime and levofloxacin, and their efficacy in vivo
using intranasal infection in BALB/c mice, as inhalation
Antibiotic mediated intracellular killing of B. mallei infected  J774A.1 murine macrophages Figure 3
Antibiotic mediated intracellular killing of B. mallei 
infected J774A.1 murine macrophages. Bacteria were 
added at an MOI of 25:1 and incubated for 2 hours at 37°C 
with 5% CO2 followed by incubation with 100 × MIC levo-
floxacin (black bars), ceftazidime (white bars) or media only 
(crossed bars). Media in control wells contained 250 μg/ml 
kanamycin for first 2 h postinfection and 100 μg/ml kanamy-
cin for the rest of the assay to prevent the growth of extra-
cellular bacteria. At 2, 4 and 8 h post treatment, cells were 
washed and lysed with 0.1% Triton X-100, followed by serial 
10-fold dilutions plated on LBG plates and incubated at 37°C 
for 2 days for CFUs determination. Experiment performed 
twice in triplicate. Errors bars represent mean ± SEM. * P < 
0.05 significant difference between time 0 and all time points 
in levofloxacin treatment, ** P < 0.01 significant difference 
between time 0 and all time points in ceftazidime treatment.
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would be the most likely route of infection in the event of
bioterrorism threat. In previous in vitro studies, ceftazi-
dime proved to be effective against B. mallei among others
including imipenem, doxycycline, piperacillin, cipro-
floxacin [8,9]. Levofloxacin demonstrates relatively high
levels of activity against B. mallei but not B. pseudomallei
[22]. Levofloxacin is known to achieve higher intracellular
concentration and is recommended for intracellular infec-
tions [23]. Our results indicate that B. mallei strain ATCC
23344 is susceptible to a concentration as low as 2.5 μg/
ml of levofloxacin and 5 μg/ml of ceftazidime. These
results confirmed prior studies evaluating susceptibility of
15 isolates of B. mallei to 35 antimicrobial agents [15]. In
this study, ceftazidime and levofloxacin appeared in the
group of most effective drugs tested in this panel against
B. mallei. However, the high percentage of resistant strains
of B. pseudomallei to levofloxacin and the emergence of
ceftazidime-resistant clinical isolates of B. pseudomallei
would affect the recommendations of these drugs as use-
ful treatment for both glanders and melioidosis, underlin-
ing the need for supplementary monitoring of the
effectiveness of the recommended antimicrobials.
The effectiveness of levofloxacin and ceftazidime in vitro
were substantiated in our in vivo experiments with all
treated mice surviving at least 34 days post infection. The
intranasal infection of mice with 5 × 105 CFUs of B. mallei
resulted in 90% death in untreated control mice. Treat-
ment with antibiotics used in this study prevented the
development of an acute lethal form of disease but lacked
the ability to provide complete clearance of the bacterial
infection. By 34 days post-infection, bacteria were largely
cleared from the lungs with no significant differences
between treatments. Interestingly, in our intranasal infec-
tion model, the spleen appears to be the major target tis-
sue for glanders infection and a site of multifocal
abscesses. Similar findings were documented in studies
with intraperitoneal glanders in mice and hamsters
[20,24]. The untreated and antibiotic-treated mice exhib-
ited a 6–10 fold increase in spleen weights compared to
healthy, uninfected animals. Bacterial loads in spleens
were significantly reduced in antibiotic treated animals
compared to untreated control but remained in the range
of 1.6 × 104 CFU/g of spleen. The antibiotics adminis-
trated 24 hours post-infection for 10 days led to the devel-
opment of a chronic, non-lethal abscess infection
suggesting that B. mallei may have the propensity for
latency, as does the very closely related organism B. pseu-
domallei [25]. Efficacy of other antibiotics tested in ham-
sters revealed that time of administration of
antimicrobials is the important factor affecting protection
against  B. mallei [24]. The experiments showed that
administration of treatment less than 24 h post-exposure
resulted in protection against the pathogen. A similar con-
clusion was obtained in antibiotics efficacy testing against
B. pseudomallei infected mice [26]. Combined, this sug-
gests that the infection could be contained or eliminated
if very early antibiotic treatment was initiated to prevent
the bacterial load from reaching a lethal dose in the host.
The pharmacokinetics of each antimicrobial, relative to
the in vitro MIC and the ability of the bacteria to reside in
privileged intracellular sites (not always easily accessible
to the antimicrobials) should be considered as an impor-
tant factor in effective treatment. For that reason, we
tested levofloxacin in our study since fluoroquinolones
are known to penetrate renal, lung and bronchial track tis-
sues achieving a high intracellular concentration exceed-
ing levels of the drug in serum [23]. Both antimicrobials
were very effective in intracellular bacterial killing reduc-
ing bacterial loads to practically undetectable levels, vali-
dating their ability as cell-permeable antibiotics.
Conclusion
The current study showed that both ceftazidime and levo-
floxacin, despite good activity in vitro against B. mallei,
failed to eradicate bacterium and resulted in development
of a chronic, non-lethal form of glanders. Both antibiotics
demonstrated some utility for treatment of glanders,
including the ability for intracellular penetration and
clearance of organisms in vitro, despite bacterial burdens
recovered in vivo following i.p. antibiotic treatment.
Methods
Bacterial strain
B. mallei strain ATCC 23344 (China 7) was cultured on
Luria-Bertani supplemented with 4% glycerol (LBG) agar
plates for 48 h at 37°C. Isolated colonies were sub-cul-
tured to LBG broth, and cultures were incubated at 37°C
until optical density readings at 600 nm (OD600) reached
an exponential phase of growth. Bacteria were pelleted by
centrifugation, washed and re-suspended in sterile 1×
phosphate-buffered saline (PBS, pH 7.4) to obtain the
desired CFU/ml. All procedures were performed in a
biosafety level 3 laboratory.
Antimicrobial susceptibility testing (MIC determination)
The minimal inhibitory concentrations of the antibiotics
were tested by the Kirby-Bauer disk diffusion method and
the dilution method as previously described (Clinical and
Laboratory Standards Institute, formerly NCCLS. 20003.
Performance standards for antimicrobial disk susceptibil-
ity tests. 309 Approved standard – Eighth Edition M2-A8,
ISBN 1-56238-485-6, CLSI. Wayne, Pa.). Briefly, fresh
antibiotic-containing disks (serial dilutions) were used for
susceptibility testing. LBG plates were inoculated with B.
mallei ATCC 23344 and disks containing the antibiotic
dilutions placed on top of the inoculated agar. The plates
were incubated at 37°C for 24–48 h. Zones were meas-
ured and the mean diameter was calculated. The interpre-
tation of results was based on the NCCLS zone diametersBMC Microbiology 2009, 9:88 http://www.biomedcentral.com/1471-2180/9/88
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used for non-Enterobacteriaceae. For the broth dilution
method, an inoculum of 105 CFU of washed B. mallei per
ml was used, and the test was conducted in LBG for 24 h
at 37°C. The interpretation of results was based on the
NCCLS MIC breakpoints for non-Enterobacteriaceae and
MIC for B. pseudomallei [16]. The inhibition of growth was
confirmed by spectrophotometrically measurements and
plating of serial dilutions onto LBG plates. Tubes contain-
ing bacteria but not antibiotic were included as a positive
growth control.
Mice
Animal studies were carried out in accordance with the
Animal Care and Use Committee's guidelines as recom-
mended by the National Institutes of Health. Female, 6- to
8-week-old, BALB/c mice were obtained from Harlan
Sprague Dawley, Inc. (Indianapolis, Indiana). Animals
were provided with rodent feed and water ad libitum and
maintained on 12 h light cycle.
Challenge with B. mallei and antimicrobial administration
Groups of 10 animals were inoculated via intranasal (i.n.)
route with 5 × 105 CFUs of B. mallei ATCC 23344, in a
total volume of 50 μl in PBS solution given to both nares.
Treatment with antibiotic via intraperitoneal route (i.p.)
started 24 hours after infection, once a day, for 10 days.
Doses of antibiotics used in this study were in the range of
high doses used in humans: ceftazidime 100 mg/kg/day
and levofloxacin 20 mg/kg/day. The animals were
weighed prior to challenge and doses of antibiotics were
adjusted accordingly. Levofloxacin (Levaquin Injection,
GlaxoSmithKline) and ceftazidime (Fortaz, Ortho-
McNeil, Inc.) were purchased through local UTMB Phar-
macy and doses for injection were prepared and stored
according to manufacturer's instructions.
Bacterial load determinations
Five animals from each group of antibiotic treated ani-
mals and survivors from non-treated control animals,
were sacrificed and lungs and spleen were harvested for
CFU determination. Organs were weighed, homogenized
in 5 ml sterile PBS, plated in duplicates on LBG and incu-
bated at 37°C for 2 days prior to CFU determinations. For
comparison, spleen weights from healthy non infected
but antibiotic treated animals were also evaluated. CFU
were expressed as the mean ± SEM. Organs (lung, spleen
and liver) from additional remaining survivors were used
for histological examinations.
B. mallei J774A.1 uptake and killing assays
Murine J774A.1 cells were seeded (5 × 105) onto Corning
Costar 24 well plates (Corning, NY) with DMEM and
incubated overnight at 37°C with 5% CO2. Bacteria were
added at an MOI of 25:1 to J774A.1 cells in duplicate. The
high MOI was used to guaranty that every macrophage
was able to take up a large number of bacteria that sur-
vived the phagocytic activity of the cell but were killed by
our experimental antibiotic treatment. Inoculated wells
were centrifuged at 800 × g for 2 minutes and incubated
for 2 hours at 37°C with 5% CO2 followed by a PBS wash
(×3) and 2, 4 and 8 hours incubation with antibiotics.
Media in control wells contained 250 μg/ml kanamycin
for first 2 h postinfection and 100 μg/ml kanamycin for
the rest of the assay to prevent the growth of extracellular
bacteria [12,13]. The concentration of antibiotics tested in
this assay was equal to 100 × MIC for each compound. At
appropriate time after incubation, cells were washed twice
with PBS and lysed with 0.1% Triton X-100, followed by
10-fold serial dilutions plated on LBG plates and incu-
bated at 37°C for 2 days prior to colony forming units
determination. Additionally, to monitor the J774A.1 cells
during experiment, LDH (lactate dehydrogenase) cytotox-
icity assay was performed according to manufacturer's
instruction (BioVision Research Products, Mountain
View, CA) at all time points.
Statistical analysis
Survival curves were calculated by Kaplan Meier survival
analysis with log-rank tests between groups using Graph-
Pad Prism (V.4.03 for windows). Comparisons of spleen
weights were performed using ANOVA and LOG trans-
formed values of bacterial load was analyzed by Student's
t-test. P value ≤ 0.05 was considered significant.
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